Abstract | OBJECTIVES: METHODS: Two- drug combinations at various concentrations below their MICs were tested for growth inhibition of M. tuberculosis using the BACTEC 460 system in vitro. Drug interactions were evaluated based on the quotient values that were derived numerically from the growth indices of cultures treated with a single antibiotic or combination treatment with two antibiotics. RESULTS: CONCLUSIONS: SQ109 interacts Synergistically with isoniazid and rifampicin, two of the most important front-line TB drugs. This finding supports efforts to further evaluate new combination therapies containing SQ109 in experimental animal models of TB that emulate future clinical trial studies in humans.
|
Authors | Ping Chen, Jackie Gearhart, Marina Protopopova, Leo Einck, Carol A Nacy |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 58
Issue 2
Pg. 332-7
(Aug 2006)
ISSN: 0305-7453 [Print] England |
PMID | 16751637
(Publication Type: Journal Article, Research Support, N.I.H., Extramural)
|
Chemical References |
- Antitubercular Agents
- Ethylenediamines
- N-geranyl-N'-(2-adamantyl)ethane-1,2-diamine
- Adamantane
- Isoniazid
- Rifampin
|
Topics |
- Adamantane
(analogs & derivatives, pharmacology)
- Antitubercular Agents
(pharmacology)
- Drug Resistance, Bacterial
(drug effects)
- Drug Synergism
- Ethylenediamines
(pharmacology)
- Humans
- Isoniazid
(pharmacology)
- Microbial Sensitivity Tests
- Mycobacterium tuberculosis
(drug effects)
- Rifampin
(pharmacology)
|